Adaptimmune secures $104 million in Series A Financing

25 September 2014

Adaptimmune Limited, a leading biotechnology company focused on the use of T-cell therapy to treat cancer and infectious disease, today announced the completion of a $104 million Series A financing round.

Please click on the link below to download the full Press Release:-

Adaptimmune secures $104 million in Series A Financing

FierceBiotech names Adaptimmune as one of its “Fierce 15” Biotech Companies of 2014

22 September 2014

Adaptimmune today announced that it has been named by FierceBiotech as one of 2014’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.

Please click on the link below to download the full Press Release:-

FierceBiotech names Adaptimmune as one of its “Fierce 15” Biotech Companies of 2014

Adaptimmune enters strategic cancer immunotherapy collaboration with GlaxoSmithKline to develop and commercialise novel cell-based therapies

2 June 2014

Adaptimmune Limited, a leading biotechnology company developing TCR engineered T-cells to treat cancer, today announced that it has entered into a strategic collaboration and licensing agreement with GlaxoSmithKline (GSK) for the development and commercialisation of its lead clinical cancer programme.

Please click on the link below to download the full Press Release:-

Adaptimmune enters strategic cancer immunotherapy collaboration with GlaxoSmithKline to develop and commercialise novel cell-based therapies

Bent Jakobsen speaking at AACR in San Diego

8 April 2014

Bent Jakobsen, CSO to Adaptimmune, is presenting at AACR in San Diego on Tuesday 8th April, 3.00pm – 5.00pm in the session entitled: “CIMT-AACR-CIMM Joint Session on Deciphering and modulating T-cell specificity in clinically effective antitumor responses”

AACR Conference

Adaptimmune announces full-time appointment of James Noble as Chief Executive Officer

26 March 2014

Adaptimmune Limited, the biotechnology company focused on the use of engineered T cells to treat cancer, today announced the full-time appointment of James Noble as Chief Executive Officer. Mr Noble has been CEO of Adaptimmune since its formation in 2008, but until now has been combining this position with his role as CEO of sister company, Immunocore. He will remain on the Board of Immunocore as a non-executive director.

Please click on the link below to download the full Press Release:-

Adaptimmune announces full-time appointment of James Noble as Chief Executive Officer

 

Adaptimmune announces award of £2.1m from the Biomedical Catalyst Fund

25 March 2014

Adaptimmune has been awarded a grant of £2.1 million from the Biomedical Catalyst Fund, managed by the UK’s innovation agency the Technology Strategy Board and the Medical Research Council. The prestigious award will expedite the development of Adaptimmune’s second engineered T cell therapy programme into the clinic in triple negative breast cancer.

Please click on the link below to download the full Press Release:-

Adaptimmune announces award of £2.1m from the Biomedical Catalyst Fund